Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

<p>Investigational New Drug application cleared by U.S. Food and Drug Administration Design leverages insights from partner’s ongoing Phase 1 trial in China that support starting dose that appears safe and clinically active based on emerging early clinical data Patient screening anticipated in December 2023, with initial data expected in second half of 2024 FOSTER CITY, […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/terns-pharmaceuticals-announces-global-phase-1-clinical-trial-design-of-tern-701-for-the-treatment-of-chronic-myeloid-leukemia/">Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>